Eyenovia Inc

NASDAQ:EYEN   3:59:43 PM EDT
5.50
+0.06 (+1.10%)
Products, Regulatory

Eyenovia Inc - Announces Positive Topline Results From Vision-1 Phase 3 Clinical Study Of Microline For The Treatment Of Presbyopia

Published: 05/25/2021 12:42 GMT
Eyenovia Inc (EYEN) - Eyenovia Inc - Announces Positive Topline Results From Vision-1 Phase 3 Clinical Study of Microline for the Treatment of Presbyopia.
Eyenovia Inc - Primary Endpoint Was Achieved With Well-tolerated Micro-array Print (map™) Safety Profile.
Eyenovia - Upcoming Key 12 Month Milestones Include Mydcombi PDUFA; Vision-2 Phase 3 Trial Results, Completion of Enrollment for Chaperone Phase 3 Trial.